Related Experiment Video
Updated: Aug 28, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Andrew Patterson1,2, Noam Auslander3
1Genomics and Computational Biology Graduate Group, University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA, 19104, USA.
Abstract:
Immune Checkpoint Inhibitor (ICI) therapy has revolutionized treatment for advanced melanoma; however, only a subset of patients benefit from this treatment. Despite considerable efforts, the Tumor Mutation Burden (TMB) is the only FDA-approved biomarker in melanoma. However, the mechanisms underlying TMB association with prolonged ICI survival are not entirely understood and may depend on numerous confounding factors. To identify more interpretable ICI response biomarkers based on tumor mutations, we train classifiers using mutations within distinct biological processes. We evaluate a variety of feature selection and classification methods and identify key mutated biological processes that provide improved predictive capability compared to the TMB. The top mutated processes we identify are leukocyte and T-cell proliferation regulation, which demonstrate stable predictive performance across different data cohorts of melanoma patients treated with ICI. This study provides biologically interpretable genomic predictors of ICI response with substantially improved predictive performance over the TMB.
Insights
New biomarkers for immune checkpoint inhibitor (ICI) therapy in melanoma show improved prediction of patient response compared to Tumor Mutation Burden (TMB). These biomarkers focus on mutations in key biological processes, offering more interpretable insights into treatment success.
Area of Science:
- Genomics and Immunology
- Cancer Therapeutics
- Biomarker Discovery
Background:
- Immune Checkpoint Inhibitor (ICI) therapy has transformed advanced melanoma treatment, but patient response varies significantly.
- Tumor Mutation Burden (TMB) is the sole FDA-approved biomarker for ICI response in melanoma, yet its predictive mechanisms are not fully understood and can be influenced by confounding factors.
- There is a critical need for more interpretable and robust biomarkers to predict ICI efficacy in melanoma patients.
Purpose of the Study:
- To identify novel, biologically interpretable biomarkers for predicting response to Immune Checkpoint Inhibitor (ICI) therapy in advanced melanoma.
- To evaluate the predictive performance of mutations within specific biological processes compared to Tumor Mutation Burden (TMB).
- To uncover key mutated biological pathways associated with improved ICI treatment outcomes.
Main Methods:
- Development and training of machine learning classifiers using mutations from distinct biological processes.
- Evaluation of various feature selection and classification algorithms to identify predictive genomic features.
- Cross-validation across different patient cohorts to ensure stable and reliable performance of identified biomarkers.
Main Results:
- Mutations within specific biological processes demonstrated superior predictive capability for ICI response compared to TMB.
- The top-performing mutated biological processes identified were regulation of leukocyte and T-cell proliferation.
- These identified biological processes showed consistent predictive performance across independent melanoma patient datasets.
Conclusions:
- Mutations in leukocyte and T-cell proliferation regulation represent promising, biologically interpretable biomarkers for predicting ICI response in melanoma.
- These novel genomic predictors offer substantially improved predictive performance over the current TMB biomarker.
- This study paves the way for more personalized and effective immunotherapy strategies in advanced melanoma.
